Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following two offers if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
10-day money back guarantee*
JOIN THE CLUB
Canadian Insider Ad-Free
$49/ year*
All benefits of basic registration
No 3rd party display ads
10-day money back guarantee*
GO AD-FREE

* Price is subject to applicable taxes. Money back guarantee: For bona fide Ad-Free or Canadian Insider Club subscribers, if you downgrade to Basic or cancel with-in 10 days of first subscribing, we will refund your payment upon request. Immediately after downgrading or cancelling, using the same email that is associated with your account, request a refund via our Contact Us form at the bottom of the page. We will only consider one refund request per household or organization. We cannot accommodate refund requests where an account holder has not provided verifiable address and billing information.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Oncolytics Biotech Inc. (T:ONC)

Business Focus: Biotechnology & Medical Research

INK Edge Outlook

This company is also listed in the United States as ONCY on the NASDAQ. Click here to get the live US quote and see if there are any SEC insider filings..
Log in or join to add this stock to your watch list.

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for ONC within the last 6 months
Loading...
See all filings within the past 6 months

Company News

May 16, 2019 07:00 ET
Oncolytics Biotech (R) Publishes Abstract Highlighting Additional Biomarker Analyses at the 2019 American Society of Clinical Oncology Annual Meeting
- Early and durable T cell clone expansion correlates with survival -- Pelareorep-induced upregulation of pro inflammatory genes was observed in patients who derived clinical benefit -- Pelareorep primes the immune system, supporting combination treatment with checkpoint inhibitors -
Read full article
May 03, 2019 07:00 ET
Oncolytics Biotech (R) Reports 2019 First Quarter Financial Results and Operational Highlights
- Recent biomarker data identifies a simple blood test that may predict clinical response to pelareorep -
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
2.85
--
--
Price to Sales - TTM
--
21.98
18.45
Price to Book - most recent quarter
7.72
3.60
3.33
Price to Cash Flow per share - TTM
--
10.77
12.41
Price to Free Cash Flow per share - TTM
--
3.24
12.85
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
May 15, 2019115,592-690
Apr 30, 2019116,28220,784
Apr 15, 201995,4985,509
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Oncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company's clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.

See business summary

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).

Twitter

Search (past week) for $ONC.CA

  • No tweets found

StockTwits

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).

Twitter

Search (past week) for $ONC.CA

  • No tweets found

StockTwits